

Call identifier: FP7-HEALTH-2009-single-stage

Date of publication: 3 September 2008.

Indicative budget: EUR 476 million – Deadline: 3 December 2008

Funding schemes:

CP-FP (Collaborative Project-Small or medium-scale Focused research project);
CP-IP (Collaborative Project-Large scale Integrating Project); NoE (Network of Excellence)
CA (Coordination and Support Action - Coordinating Action)
SA (Coordination and Support Action - Supporting Action)

1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

1.2 DETECTION, DIAGNOSIS AND MONITORING

- **1.2-1: Development of tools for sensitive and specific in vitro detection of proteins and their interactions for diagnostic, prognostics and monitoring purposes.** CP-FP, max € 6m (1 or more projects)
- **1.2-2: Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of relevant disorders.** CP-FP, max € 3m (1 or more projects)
- **1.2-3: Novel MR-compatible PET detectors for simultaneous PET/MRI imaging.** CP-IP, min € 6m – max € 12m (max 1 project)
- **1.2-4: Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy.** CP-FP, max € 6m (max 1 project)
- **1.2-5: Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes relevant to the diagnosis and/or monitoring of diseases.** CP-FP, max € 6m (1 or more projects)
- **1.2-6: Evaluation of the potential health impact of Diagnostic Imaging agents doses.** SA, max € 0.5m (max 1 project for each area)

Scientific officers: Philippe JEHENSON (philippe.jehenson@ec.europa.eu); Jean-Luc SANNE (jean-luc.sanne@ec.europa.eu); Torbjörn INGEMANSSON (torbjorn.ingemansson@ec.europa.eu) - (RTD F.5)

1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES

- **1.3-1: New initiatives towards the implementation of the Replace, Reduce and Refine strategy.** CA, max € 1m (max 1 project)

Scientific officer: Jürgen BÜSING (juergen.buesing@ec.europa.eu) - (RTD F.5)

1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS

- **1.4-1: Cell therapy for tissue and organs.** CP-IP(s), min € 6m - max € 12m (1 or more projects)
- **1.4-2: Regeneration of tissue using bio-compatible materials and cells.** CP-IP(s), min € 6m - max € 12m (1 or more projects)
- **1.4-3: Activation of endogenous cells as an approach to regenerative medicine.** CP-IP(s), min € 6m - max € 12m (1 or more projects)

Scientific officers: Charles KESSLER (charles.kessler@ec.europa.eu); Fatiha SADALLAH (fatiha.sadallah@ec.europa.eu); Jürgen SAUTTER (juergen.sautter@ec.europa.eu) - (RTD F.5)

2. TRANSLATING RESEARCH FOR HUMAN HEALTH

2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING

- **2.2-1: Brain and brain-related diseases**
 - **2.2.1-1: Synaptopathies: genesis, mechanisms and therapy.** CP-IP, min € 6m - max € 12m (max 1 project)
 - **2.2.1-2: Identifying genetic and environmental interactions in schizophrenia.** CP-IP, min € 6m - max € 12m (max 1 project)
 - **2.2.1-3: Optimising current therapeutic approaches to schizophrenia.** CP-IP, min € 6m - max € 12m (max 1 project)

2.2.1-4: Understanding the blood brain barrier (BBB) to improve drug delivery to the brain.
CP-FP, max € 3m (one or more projects)

2.2.1-5: Psycho-social factors of brain disorders. CA, max € 1.5m. (max. 1 project)

Scientific officers: **Patrizia TOSETTI** (patrizia.tosetti@ec.europa.eu); **Véronique BERNARD** (veronique.bernard@ec.europa.eu);
(RTD F.2)

- **2.2-2: Human Development and ageing - (Temporary closure of this area – No topics in this call)**

2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

- **2.3-1: Anti-microbial drug resistance including fungal pathogens**

2.3.1-1: Global collaborative research on the prevention of antibiotic resistance.
CP-IP, min € 6m - max € 12m (max. 1 project)

2.3.1-2: Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human host.
CP-FP, max € 6m (1 or more projects)

2.3.1-3: Clinical evaluation of point-of-care diagnostic tests for microbial detection and identification, antibiotic susceptibility determination and biomarkers - CP-FP, max € 6m (1 or more projects)

Scientific officers: **Cornelius SCHMALTZ** (cornelius.schmaltz@ec.europa.eu); **Jonas BUNIKIS** (jonas.bunikis@ec.europa.eu); -
(RTD F.3)

- **2.3-2: HIV/AIDS, malaria and tuberculosis**

2.3.2-1: Integration of European efforts in research on malaria. NoE, min € 6m – max € 12m (max 1 project)

Scientific officer: **Andreas HOLTEL** (andreas.holtel@ec.europa.eu); - (RTD F.3)

2.3.2-2: Identification and pre-clinical testing of new vaccine candidates for tuberculosis.
CP-IP, min € 6m – max € 12m (max 1 project)

Scientific officer: **Hannu LAANG** (hannu.laang@ec.europa.eu); - (RTD F.3)

2.3.2-3: Discovery and/or development of new and promising anti-HIV microbicides.
CP-IP, min € 6m – max € 12m (max 1 project)

2.3.2-4: Mucosal and topical vaccines for poverty related diseases (HIV/AIDS, malaria and/or TB).
CP-IP, min € 6m – max € 12m (max 1 project)

2.3.2-5: Translational vaccine research for poverty-related diseases (HIV/AIDS, malaria and/or TB).
CP-FP, max € 3m (max 1 project)

Topic to be implemented through ERA-NET joint call (with a distinct deadline):

2.3.2-6: ERA-NET for stepping up European co-operation in HIV/AIDS research.
ERA-Net CA, max € 2m (max 1 project)

Scientific officers: **Manuel ROMARIS** (manuel.romaris@ec.europa.eu) **Teresa DE MAGISTRIS** (maria-teresa.de-magistris@ec.europa.eu), **Gianluca QUAGLIO** (gianluca.quaglio@ec.europa.eu), - (RTD F.3)

- **2.3-3: Potentially new and re-emerging epidemics**

2.3.3-1: Efficacy and effectiveness of personal protection equipment and other measures against influenza transmission. CP-FP, max € 3m (max 1 project)

Scientific officers: **Cornelius SCHMALTZ** (Cornelius.schmaltz@ec.europa.eu); **Jonas BUNIKIS** (jonas.bunikis@ec.europa.eu)
(RTD F.3)

- **2.3-4: Neglected infectious diseases - Published under area 4.3.1**

2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

- **2.4-1: Cancer - (Temporary closure of this area – No topics in this call)**

- **2.4-2: Cardiovascular diseases**

2.4.2-1: Improved or new therapeutic approaches for the treatment of heart failure.
CP-IP, min € 6m – max € 12m (max 1 project)

2.4.2-2: Cardiac arrhythmias: from genes to improved management of patients.
CP-IP, min € 6m – max € 12m (max 1 project)

2.4.2-3: Translation of basic knowledge on inherited cardiomyopathies into clinical practice.
CP-FP, max € 3m (1 or more projects)

Scientific officers: **Virginija DAMBRAUSKAITE** (virginija.dambrauskaite@ec.europa.eu);
Diana OBELIENIENE (diana.obelieniene@ec.europa.eu) - (RTD F.2)

- **2.4-3: Diabetes and obesity**

- **2.4.3-1: Novel therapeutical approach to pregnancy-induced diabetes.** CP-FP, max € 3m (max 1 project)

- **2.4.3-2: Novel immunotherapies for type 1 diabetes.** CP-IP, min € 6m – max € 12m (max 1 project)

- **2.4.3-3: Molecular pathways in food intake at CNS-liver-gut regulation level.** CP-FP, max € 3m (max 1 project)

Scientific officer: **Nathalie VERCRUYSSSE** (nathalie.vercruysse@ec.europa.eu) - (RTD F.2)

- **2.4-4: Rare diseases**

- **2.4.4-1: Rare neurological diseases.** CP-FP, max € 6m (1 or more projects)

- **2.4.4-2: Preclinical development of substances with a clear potential as orphan drugs.** CP-FP, max € 3m (1 or more projects)

Scientific officer: **Catherine BERENS** (catherine.berens@ec.europa.eu) - (RTD F.2)

- **2.4-5: Other chronic diseases**

- **2.4.5-1: Prevention and treatment of non-alcoholic fatty liver disease (NAFLD).** CP-FP, max € 6m (1 or more projects)

- **2.4.5-2: Cellular and molecular mechanisms of the development of chronic kidney disease (CKD).** CP-IP, min € 6m - max € 12m (max 1 project)

Scientific officers: **Grigorij KOGAN** (grigorij.kogan@ec.europa.eu), **Stefan WAGENER** (stefan.wagener@ec.europa.eu) (RTD F.2)

3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS

3.1 TRANSLATING CLINICAL RESEARCH INTO PRACTICE

- **3.1-1: Patient safety: Effective implementation of prevention strategies for healthcare associated infections.**

- CP-FP, max € 3m (1 or more projects)

- **3.1-2: Improve quality and safety of hospital care.** CP-FP, max € 3m (1 or more projects)

- **3.1-3: Complementary and alternative medicine.** CA, max € 1.5m (max 1 project)

- **3.1-4: Improved treatment of chronic diseases in developing countries.** CP-FP, max € 3m (1 or more projects)

Scientific officer: **Jan PAEHLER** (jan.paehler@ec.europa.eu) - (RTD F.2)

3.2 HEALTHCARE SYSTEMS

- **3.2-1: Organisation of dementia care.** CP-FP, max € 3m (1 or more projects)

- **3.2-2: Healthcare outcomes and cost-benefits.** CP-FP, max € 3m (1 or more projects)

- **3.2-3: Primary care quality linkage to costs.** CP-FP, max € 3m (1 or more projects)

- **3.2-4: Impact of cross border collaboration on health services.** CP-FP, max € 6m (1 or more projects)

- **3.2-5: Research access to comparable healthcare data.** CA, max € 1.5m (max 1 project)

- **3.2-6: Scoping study to address the methodological challenges of quantifying the socio-economic burden of brain diseases compared to other major diseases.** SA, max € 0.5m (max 1 project)

Scientific officer: **Oyvind HOPE** (oyvind.hope@ec.europa.eu) - (RTD F.2)

3.3 ENHANCED HEALTH PROMOTION AND DISEASE PREVENTION

- **3.3-1: Child and adolescent mental health.** CP-FP, max € 3m (1 or more projects)

- **3.3-2: Environmental prevention of substance abuse by adolescents.** CP-FP, max € 3m (1 or more projects)

- **3.3-3: Ageing cohorts.** CP-IP, min € 6m - max € 12m (max 1 project)

- **3.3-4: Birth/mother-child cohorts co-ordination.** CA, max € 1.5m (max 1 project)

- **3.3-5: European child health research platform.** CA, max € 1.5m (max 1 project)

Scientific officer: **Gesa HANSEN** (gesa.hansen@ec.europa.eu) - (RTD F.2)

4. OTHER ACTIONS ACROSS THE HEALTH THEME

4.1 COORDINATION & SUPPORT ACTIONS ACROSS THE THEME

- **4.1-1: Monitoring tool and technology transfer analysis for health grants during FP7.** SA, max € 1m (max 1 project)
- **4.1-2: Dissemination of results from research in Life Sciences and Biotechnology for Health to the general public and/or information multipliers.** CA or SA, max € 1m (1 or more projects)
- **4.1.3: Targeting publication bias.** SA, max € 0.5m (max 1 project)

Scientific officers: **Josefina ENFEDAQUE** (josefina.enfedaque@ec.europa.eu);
Ludovica SERAFINI (ludovica.serafini@ec.europa.eu) - (RTD F.1)

4.2 RESPONDING TO EU POLICY NEEDS

- **4.2-1: Adapting off-patent medicines to the specific needs of paediatric populations.** CP-FP, max € 6m (1 or more projects)
- **4.2-2: Study of the arrhythmogenic potential of different classes of medicines.** CP-FP, max € 3m (1 or more projects)
- **4.2-3: Human Papillomavirus Vaccination (HPV) and cervical cancer screening programmes: estimate of impact of different policy options by way of disease modelling and health economics.** CP-FP, max € 3m (max 1 project)
- **4.2-4: Coordinating action on organ procurement & transplantation with a focus on new EU Member States.** CA, max € 1.5m (max 1 project)

Scientific officers: **Fergal DONNELLY – (RTD F.5)** (fergal.donnelly@ec.europa.eu);
Cornelius SCHMALTZ – (RTD F.3) (cornelius.schmaltz@ec.europa.eu)

4.3 SICAs – SPECIFIC INTERNATIONAL COOPERATION ACTIONS

- **4.3-1: Neglected infectious diseases**

4.3.1-1: Discovery and development of new vaccines or drugs for helminth infections – Target region: ICPC (International Cooperation Partner Countries). CP-FP, max € 6m (1 or more projects)

4.3.1-2: Identification and development of vaccine candidates for neglected bacterial infections – Target region: ICPC. CP-FP, max € 6m (1 or more projects)

4.3.1-3: Human immune responses to co-infections of poverty-related (HIV, malaria, TB) and neglected infectious diseases – Target region: ACP (African, Caribbean and Pacific countries). CP-IP, min € 6m - max € 12m (max 1 project)

Scientific officers: **Ole OLESEN** (ole.olesen@ec.europa.eu); **Rachida GHALOUCI** (rachida.ghalouci@ec.europa.eu) – (RTD F.3)

- **4.3-2: International Public Health and Health Systems**

4.3.2-1: Strategies and interventions for improving reproductive health - Target region: ICPC. CP-FP, max € 3m (1 or more projects)

4.3.2-2: Access to medicines – Target region: ICPC. Funding scheme: CP-FP, max € 3m (1 or more projects)

4.3.2-3: Integration of disease surveillance and health systems response – Target region: ACP or Asian countries. Funding scheme: CP-FP, max € 3m (1 or more projects)

Scientific officer: **Albrecht JAHN** (albrecht.jahn@ec.europa.eu) - (RTD F.2)

- **4.3-3: Coordinated topics with Russia**

4.3.3-1: Comparative population genetic studies on multifactorial diseases - Target region: Russia. CP-FP, max € 3m (max 1 project)

4.3.3-2: Mechanisms of diabetic and weight-related co-morbidity in heart failure – Target region: Russia. CP-FP, max € 3m (max 1 project)

Scientific officer: **Indridi BENEDIKTSSON** (indridi.benediktsson@ec.europa.eu) - (RTD F.5)

Call identifier: FP7-HEALTH-2009-two-stage
Date of publication: 3 September 2008.
Indicative budget: EUR 115 million – First deadline: 3 December 2008
Funding scheme:
CP-IP (Collaborative Project-Large scale Integrating Project)

1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

1.1 HIGH-THROUGHPUT RESEARCH

- **1.1-1: Computational tools for genome annotation and genotype/phenotype data integration.**
CP-IP(s), min € 6m – max € 12m (1 or more projects)
- **1.1-2: High throughput tools and technologies to analyse samples in large-scale human biobanks.**
CP-IP(s), min € 6m – max € 12m (1 or more projects)
- **1.1-3: Tools , technologies and resources for the characterisation of protein functions.**
CP-IP(s), min € 6m – max € 12m (1 or more projects)

Scientific officers: **Frederick MARCUS** (frederick.marcus@ec.europa.eu); **Iiro EEROLA** (iiro.eerola@ec.europa.eu);
Ioanna.SISKA (ioanna.siska@ec.europa.eu); **Thomas DYLAG** (thomas.dylag@ec.europa.eu);
Jacques REMACLE (jacques.remacle@ec.europa.eu) – (RTD F.4)

2. TRANSLATING RESEARCH FOR HUMAN HEALTH

2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES

- **2.1-1: Large-scale data gathering**
 - 2.1.1-1: Large-scale functional genomics effort in multi-cellular organisms to elucidate the function of human genes products.**
 - 2.1.1-2: Large-scale functional genomics efforts to identify molecular determinants of cancer.**
 - 2.1.1-3: Characterisation of human genetic variation in Europe.**CP-IP(s), min € 6m - max € 12m (1 or more projects)

Scientific officers: **Christian DESAINTEs** (christian.desaintes@ec.europa.eu);
Jacques REMACLE (Jacques.remacle@ec.europa.eu); **Iiro EEROLA** (iiro.eerola@ec.europa.eu);
Ioanna.SISKA (ioanna.siska@ec.europa.eu) – (RTD F.4)

- **2.1-2: Systems biology**
 - 2.1.2-1: Systems biology approaches for basic biological processes relevant to health and disease.**CP-IP(s), min € 6m - max € 12m (1 or more projects)

Scientific officers: **Bernard MULLIGAN** (Bernard.mulligan@ec.europa.eu);
Christina KYRIAKOPOULOU (christina.kyriakopoulou@ec.europa.eu);
Frederick MARCUS (frederick.marcus@ec.europa.eu); **Jacques REMACLE** (Jacques.remacle@ec.europa.eu);
(RTD F.4)

LEGAL NOTICE

Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of the following information.